Currently, targeted therapies for patients with locally advanced unresectable or metastatic gastric cancer mainly consist of anti-HER2 Mabs, anti-angiogenic drugs, and PD-1 inhibitors [120]. Here, ERBB2 is linked to gastric cancer.